MBWE MPOH, Maurice; DELI, Vandi; DANIEL, Tollo Tollo; SALVO, Francesco

doi:10.4103/ijmy.ijmy_88_23

Bordeaux population health [BPH]

DELI, Vandi

DANIEL, Tollo Tollo

Langue

Article de revue

Ce document a été publié dans

International Journal of Mycobacteriology. 2023-06-15, vol. 12, n° 2, p. 168-174

Résumé en anglais

Recognized in 1994 as a global emergency by the World Health Organization, tuberculosis (TB) remains an ongoing health threat. In Cameroon, the mortality rate is estimated at 2.9%. Treatment of multidrug-resistant TB (MDR-TB) defined as the resistance to the two most effective antiTB drugs, and requires therapy of more than 7 drugs taken on a daily basis during 9-12 months. This study aimed to evaluate the safety profile of treatment regimens used for MDR-TB at Jamot Hospital of Yaounde (JHY). This was a retrospective cohort study of patients treated for MDR-TB at HJY from January 1, 2017, to December 31, 2019. Patients characteristics of the cohort, drugs regimen were collected and described. All possible adverse drug reactions (ADR) were described clinically and by severity grade. During the study period, 107 patients were included, and 96 (89.7%) experienced at least one ADR. Most parts of the patients (90) experienced mild or moderate ADR. Hearing loss was the most frequent ADR, and led mostly in aminoglycosides dose reduction (n = 30, 96.7%). Gastrointestinal events were commonly observed during the study period. Our findings suggested that ototoxicity was a prominent safety issue during the study period. The implementation of the new short treatment regimen could be effective in reducing the burden of ototoxicity among MDR-TB patients. Nevertheless, new safety issues could emerge.< Réduire

Mots clés en anglais

Humans

Antitubercular Agents

Cameroon

Ototoxicity

Retrospective Studies

Tuberculosis

Multidrug-Resistant

Male

Female

Adult

Middle Aged

Cohort Studies

Hearing Loss

Time Factors

URI

https://oskar-bordeaux.fr/handle/20.500.12278/184666

DOI

http://dx.doi.org/10.4103/ijmy.ijmy_88_23

Projet Européen

European programme in Pharmacovigilance and Pharmacoepidemiology

Unités de recherche

Bordeaux Population Health Research Center (BPH) - UMR 1219

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Safety of antituberculosis agents used for multidrug-resistant tuberculosis among patients attending the Jamot Hospital of Yaounde, Cameroon